This international, multicentre randomized controlled trial (RCT) studies the effects of HOPE in extended criteria liver grafts donated after brain death (ECD-DBD). 46 patients were randomly assigned to receive a liver preserved with either SCS alone, or SCS followed by a short period (median: 2h 15min) of HOPE prior to transplantation. Compared to SCS, end-ischemic HOPE using Liver Assist significantly reduced signs of early allograft injury, as demonstrated by a 47% decrease in serum peak ALT within the first 7 days post-transplant (primary endpoint). In addition, recipients of HOPE-treated livers presented with fewer major postoperative complications (Clavien-Dindo grade ≥ 3; 44% vs 78%, p=0.036), had a lower comprehensive complication index (CCI: 32 vs 52, p=0.021), and spent less time in hospital and ICU.
“/…/ the overall procedural costs after transplanting patients with HOPE was 13,000€ lower compared to the SCS group”, Czigany et al 2021
Ann Surg | 2021 | doi:10.1097/sla.0000000000005110
